“A patent without commercialization is only an expensive piece of paper”
UA Office of Technology Transfer
The Austen BioInnovation Institute in Akron (ABIA) and University of Akron Research Foundation’s (UARF) “Innovative Solutions for Invention Xceleration (ISIX)” focuses on the innovation process with an emphasis on strengthening the specific steps that lead to effective, efficient commercialization at the intersection of biomedicine and advanced biomaterials.
In order to effectively deploy resources to develop ideas, it is critical to assess their technical and commercial potential, which is a key element of the ISIX process. ABIA’s MDDC leadership and UARF bring many years of successful experience to evaluating the technical and commercial potential of inventions prior to patent prosecution and prototype development. Another key feature of the ISIX project is to focus attention on those ideas that, when patented, will form the basis for new companies or licensing opportunities. Historically, many invention disclosures by clinicians and/or academic faculty that are patented never make it to market. Due diligence vetting by ISIX’s business and capital community is critical to ensure market potential. There should be a 1:1 match between patents and commercialized technologies that stem from ISIX.
The ISIX concept creates an unprecedented capacity for successful commercialization, providing an infrastructure for:
All phases and critical components in the process of creating new biomedical products
Clinician/Researcher/Engineer/Entrepreneur/Business engagement early in the invention process
Expertise in testing and real-time technology/product evaluation
End-user and manufacturer input into prototype design
Expert prototype design and analysis
*Quote provided by the University of Akron Research Foundation (UARF), Akron, Ohio